MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19

• Autor(a) principal: Bumiller-Bini,Valéria
• Data de Publicação: 2021
• Outros Autores: de Freitas Oliveira-Toré,Camila, Carvalho,Tamyres Mingorance, Kretzschmar,Gabriela Canalli, Gonçalves,Letícia Boslooper, Alencar,Nina de Moura, Gasparetto Filho,Miguel Angelo, Beltrame,Marcia Holsbach, Winter Boldt,Angelica Beate
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Genetics and Molecular Biology
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572021000200310
• topic: COVID-19; complement system; lectin pathway; MASP; coagulation

Abstract Components of the complement system and atypical parameters of coagulation were reported in COVID-19 patients, as well as the exacerbation of the inflammation and coagulation activity. Mannose binding lectin (MBL)- associated serine proteases (MASPs) play an important role in viral recognition and subsequent activation of the lectin pathway of the complement system and blood coagulation, connecting both processes. Genetic variants of MASP1 and MASP2 genes are further associated with different levels and functional efficiency of their encoded proteins, modulating susceptibility and severity to diseases. Our review highlights the possible role of MASPs in SARS-COV-2 binding and activation of the lectin pathway and blood coagulation cascades, as well as their associations with comorbidities of COVID-19. MASP-1 and/or MASP-2 present an increased expression in patients with COVID-19 risk factors: diabetes, arterial hypertension and cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, and cerebrovascular disease. Based also on the positive results of COVID-19 patients with anti-MASP-2 antibody, we propose the use of MASPs as a possible biomarker of the progression of COVID-19 and the investigation of new treatment strategies taking into consideration the dual role of MASPs, including MASP inhibitors as promising therapeutic targets against COVID-19.